Active Share (vs S&P 500): 100.0%
· vs QQQ: 100.0%
— share of the book that differs from index weights (higher = more active)
· ranking
Est. Qtr Return (Q2 2026 → Q3 2026):
-15.8%
· vs SPY
-17.9%
· Prev Value $471.62M
— last quarter positions weighted by this quarter price moves
· ranking
Est. QTD Return (Q3 2026 → newest close):
+2.4%
· vs SPY
+0.3%
· Latest Value $299.32M
— latest reported positions valued at quarter-to-date price moves (still in progress)
· ranking
In its Q3 2026 13F filing, Aisling Capital Management LP disclosed 14 equity positions with a combined reported value of $299.32M. The filing implies a focused portfolio: its ten largest positions account for 98.5% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2026 were BBIO ($203.30M), SNDX ($24.76M), CMPS ($21.55M). By sector, the heaviest allocations are Health Care 100.0%.
Versus the prior quarter, Aisling Capital Management LP opened 0 new positions, trimmed 3 and fully exited 0, a turnover rate of 21.4% of positions. The portfolio's overlap with the prior quarter was 100% of names.
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
Insider Transactions (Form 4)
Latest Aisling Capital Management LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Aisling Capital Management LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 14 US equity positions with a combined value of $471.62M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Regulatory AUM (Form ADV): $716.44M as of 2026-03-27
Client mix (by RAUM): pension and profit-sharing plans 100%
Manages 2 private funds
Website: aislingcapital.com
Portfolio Structure
14 positions · $471.62M reported value (Q2 2026)
Top 10 holdings = 99.0% of reported value
Largest position: BBIO (BRIDGEBIO PHARMA INC COM) at 72.5%
Average position size: $33.69M
Sector Tilt
Health Care 100.0%
(classified holdings cover 100% of value)
Quarterly Activity
Q2 2026: 1 new, 1 reduced
12 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
AI Rebalance Analysis
1. Overall direction and market view: The fund reduced exposure to its top holding (BBIO) while adding to mid-tier positions (CMPS), suggesting a tactical shift within healthcare biotech/therapeutics, possibly to rebalance concentration risk or capitalize on specific opportunities.
2. Key moves:
- Reduced: BBIO (-32.7% shares, -4.56% weight) and BCAX (-3.5% shares, -0.17% weight).
- Added: CMPS (+20.9% shares, +2.90% weight).
- No new positions added; all others held steady.
3. Portfolio structure: Highly active, concentrated in Health Care (biotech/therapeutics), with high conviction in a few names (BBIO dominates at 67.92%). Risk appetite appears aggressive, given focus on speculative clinical-stage biotechs.
4. Per-holding one-liner:
- BBIO: BRIDGEBIO PHARMA INC (biopharma, unverified pipeline).
- SNDX: SYNDAX PHARMACEUTICALS INC (epigenetics cancer drugs, unverified).
- CMPS: COMPASS PATHWAYS PLC (psilocybin therapy, unverified).
- GLUE: MONTE ROSA THERAPEUTICS INC (cell therapy, unverified).
- BCAX: BICARA THERAPEUTICS INC (targeted protein degraders, unverified).
- URGN: UROGEN PHARMA LTD (urology treatments, unverified).
- BBOT: BRIDGEBIO ONCOLOGY THERAPEUT (oncology, unverified).
- EPRX: Eupraxia Pharmaceuticals Inc (neurodegeneration, unverified).
- BMEA: BIOMEA FUSION INC (protein engineering, unverified).
- ACRS: ACLARIS THERAPEUTICS INC (dermatology/autoimmune, unverified).
5. Style summary: Concentrated healthcare biotech fund with active rebalancing to reduce top-heavy exposure while selectively adding mid-cap positions.
Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-14 05:12
Every 13F share count is marked to the quarter-end close, rebuilding the NAV this
portfolio would have earned had it done nothing all quarter. This is a historical
reconstruction from already-public filings and prices — not a model forecast, so
precision/recall do not apply.
2023-Q3 = 100. Solid = reconstructed NAV, dashed = SPY benchmark.
Prices are split-adjusted closes and exclude dividends, so dividend-heavy
portfolios would in reality sit slightly above this line.
Why there is no forecast NAV
Not published because:
Forecast basket missing daily prices
Source: full 13F positions marked to quarter-end closes (computed 2026-11-02 01:13:11).
Share counts and prices are used as a ratio, so splits cancel out.
Holdings Prediction Model
Predicts next-quarter Top-10 holdings and weights from the fund's own historical
trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative
volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through
quarter T. Weights are shares of the modelled portfolio.
The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.
★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.
Barra Factor Attribution
The disclosed long US equity book from the 2026-Q3 13F is held at its
report-date weights and decomposed over 2026-09-30 ~ 2026-11-12.
The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional
factor returns and an EWMA factor covariance for risk. The “portfolio” is the
visible 13F book, not the fund's true NAV.
The quarter is not complete yet; the window ends at the latest available price date, 2026-11-12, and will update as prices arrive.
Portfolio return+20.63%Buy & hold
QQQ synthetic benchmark-11.15%Liquidity weighted
Excess return+31.78%vs benchmark
Barra annualised vol54.4%Model estimate
Realised vol32.8%Annualised in window
Weighted beta1.12Raw exposure
Factor / specific risk27% / 73%Share of variance
Top-10 concentration100.0%Of reported value
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.
1. Performance
Metric
Value
Note
Portfolio return (buy & hold)
+20.63%
Disclosed long book
QQQ synthetic benchmark
-11.15%
Liquidity-weighted constituents
Model universe, equal weight
+2.04%
Opportunity-cost reference
Excess return
+31.78%
Portfolio − benchmark
Arithmetic return sum
+19.45%
Difference vs compounded is the cross term
Weighted raw beta
1.12
Weighted holding betas
Realised volatility (annualised)
32.84%
Daily returns in window
Barra model volatility (annualised)
54.43%
Factor + specific
Factor share of variance
27.0%
Barra factors
Specific share of variance
73.0%
Stock residuals
Reported value
$205.3M
13F long US equity
2. Return attribution
The +19.45% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.
Factor group
Factors
Contribution
Share of |return|
Size & Liquidity
6
+2.42%
12.5%
Momentum & Growth
3
-2.51%
-12.9%
Volatility & Tail Risk
7
+3.50%
18.0%
Industry
12
+9.47%
48.7%
Specific
1
+6.57%
33.8%
Factor
Type
Exposure
Factor return
Contribution
Share of |return|
Kurtosis
Style
+2.12
+6.17%
+13.06%
67.2%
Health Care
Industry
+1.00
+9.47%
+9.47%
48.7%
Specific
Specific
—
—
+6.57%
33.8%
Size
Style
-1.24
-1.93%
+2.39%
12.3%
Short-term Reversal
Style
+1.39
+1.12%
+1.55%
8.0%
Residual Volatility
Style
+0.67
+2.15%
+1.44%
7.4%
Beta
Style
+0.27
+4.92%
+1.32%
6.8%
Leverage (Downside Vol)
Style
-0.33
-3.05%
+1.01%
5.2%
Turnover
Style
-0.10
-4.35%
+0.43%
2.2%
Amihud Illiquidity
Style
+1.33
+0.30%
+0.40%
2.0%
Liquidity
Style
-0.43
-0.20%
+0.09%
0.5%
Non-linear Size
Style
+1.25
+0.07%
+0.09%
0.4%
Max Drawdown
Style
+0.43
-1.01%
-0.43%
-2.2%
Mid Cap
Style
+0.50
-1.92%
-0.97%
-5.0%
Momentum
Style
+0.55
-3.32%
-1.81%
-9.3%
Growth
Style
-1.49
+1.50%
-2.24%
-11.5%
Historical Volatility
Style
+0.26
-9.82%
-2.57%
-13.2%
Skewness
Style
+2.16
-4.77%
-10.32%
-53.1%
3. Risk attribution
Annualised volatility is 54.43%; factor risk explains 27.0% of variance and specific risk 73.0%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.
Factor
Type
Exposure
Share of variance
Vol contribution
Share of vol
Specific
Specific
—
73.0%
+39.75%
39.8%
Health Care
Industry
+1.00
10.8%
+5.86%
5.9%
Skewness
Style
+2.16
7.6%
+4.12%
4.1%
Growth
Style
-1.49
4.3%
+2.36%
2.4%
Size
Style
-1.24
2.7%
+1.46%
1.5%
Kurtosis
Style
+2.12
2.1%
+1.14%
1.1%
Momentum
Style
+0.55
1.0%
+0.54%
0.5%
Beta
Style
+0.27
0.7%
+0.36%
0.4%
Amihud Illiquidity
Style
+1.33
0.6%
+0.34%
0.3%
Liquidity
Style
-0.43
0.3%
+0.19%
0.2%
Mid Cap
Style
+0.50
0.3%
+0.15%
0.1%
Historical Volatility
Style
+0.26
-0.2%
-0.11%
-0.1%
Max Drawdown
Style
+0.43
-0.6%
-0.33%
-0.3%
Non-linear Size
Style
+1.25
-0.6%
-0.33%
-0.3%
Short-term Reversal
Style
+1.39
-0.6%
-0.33%
-0.3%
Leverage (Downside Vol)
Style
-0.33
-0.6%
-0.34%
-0.3%
Residual Volatility
Style
+0.67
-0.7%
-0.36%
-0.4%
4. Style exposures
Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.
Style factor
Portfolio
QQQ benchmark
Difference
Size
-1.24
+2.10
-3.34
Non-linear Size
+1.25
+1.68
-0.43
Mid Cap
+0.51
+0.13
+0.38
Beta
+0.27
+1.29
-1.03
Momentum
+0.55
+0.72
-0.17
Short-term Reversal
+1.39
-0.64
+2.03
Residual Volatility
+0.67
-0.40
+1.07
Historical Volatility
+0.26
+0.86
-0.60
Liquidity
-0.43
+0.11
-0.55
Amihud Illiquidity
+1.33
+1.16
+0.17
Turnover
-0.10
+0.21
-0.31
Growth
-1.49
+0.58
-2.08
Leverage (Downside Vol)
-0.33
+0.14
-0.48
Skewness
+2.16
+0.24
+1.92
Kurtosis
+2.12
+0.21
+1.90
Max Drawdown
+0.43
-0.08
+0.51
5. Industry allocation & Brinson
Sector
Portfolio
Benchmark
Portfolio ret
Benchmark ret
Allocation
Selection
Interaction
Total
Health Care
100.0%
1.7%
+20.64%
+9.50%
+19.56%
+0.19%
+10.95%
+20.48%
Information Technology
0.0%
73.6%
+0.00%
-16.67%
+4.61%
+12.27%
-12.27%
+12.27%
Communication Services
0.0%
2.6%
+0.00%
-12.15%
+0.05%
+0.32%
-0.32%
+0.32%
Utilities
0.0%
0.8%
+0.00%
+10.14%
-0.16%
-0.08%
+0.08%
-0.08%
Consumer Staples
0.0%
0.8%
+0.00%
+15.33%
-0.22%
-0.13%
+0.13%
-0.13%
Consumer Discretionary
0.0%
8.8%
+0.00%
+5.93%
-1.44%
-0.52%
+0.52%
-0.52%
Industrials
0.0%
11.1%
+0.00%
+7.87%
-2.03%
-0.87%
+0.87%
-0.87%
Total
+20.28%
+11.14%
-0.00%
+31.42%
6. Holdings & contribution
Symbol
Name
Sector
Weight
Return
Contribution
QoQ
BBIO
BRIDGEBIO PHARMA INC
Health Care
99.01%
+20.88%
+20.67%
Reduce
SRRK
SCHOLAR ROCK HLDG CORP
Health Care
0.99%
-3.56%
-0.03%
Reduce
Contribution rank
Symbol
Sector
Weight
Return
Contribution
1
BBIO
Health Care
99.01%
+20.88%
+20.67%
2
SRRK
Health Care
0.99%
-3.56%
-0.03%
7. Conclusions
Over the attribution window 2026-09-30 → 2026-11-12 (31 trading days), the reported portfolio returned +20.63%, versus -11.15% for the QQQ synthetic benchmark — an excess of +31.78%.
Return attribution: the largest positive style/industry contributions came from Kurtosis +13.06%, Health Care +9.47%, Size +2.39%; the largest drags came from Skewness -10.32%, Historical Volatility -2.57%, Growth -2.24%. Specific (stock-level) return contributed +6.57%.
Risk attribution: Barra model volatility is 54.43% annualised; factor risk explains 27% of variance and specific risk 73%. The largest factor risk sources are Health Care 10.8%, Skewness 7.6%, Growth 4.3%.
Style tilt: size -1.24, momentum +0.55, volatility +0.26, liquidity -0.43; the weighted raw beta is 1.12. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +20.28%, selection +11.14% and interaction -0.00%.
Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.
FAQ
What did Aisling Capital Management LP buy in 2026-Q3?
In its 2026-Q3 13F filing, Aisling Capital Management LP reported 14 equity positions worth $299.32M in aggregate; its largest disclosed positions were BBIO ($203.30M), SNDX ($24.76M), CMPS ($21.55M).
How large is Aisling Capital Management LP's portfolio?
Aisling Capital Management LP reported $299.32M of long equity holdings across 14 positions as of 2026-Q3. Top-10 holdings account for 98.5% of reported value.
What is Aisling Capital Management LP's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.
Embed this fund on your site
Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.
<iframe src="https://holdingshub.top/funds/aisling-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>